Receptor (biochemistry) Study Guide

📖 Core Concepts Ligand – a molecule (protein, peptide, neurotransmitter, hormone, drug, toxin, ion, or microbial component) that binds to a receptor, usually from outside the cell. Receptor – a protein that receives a chemical messenger and converts the binding event into a cellular response. Endogenous ligand – a naturally produced substance that specifically activates its receptor. Receptor locations Cell‑surface (transmembrane): ligand‑gated ion channels, G‑protein‑coupled receptors (GPCRs), enzyme‑linked hormone receptors. Intracellular: cytoplasmic receptors, nuclear receptors. Structural families Ionotropic (ligand‑gated ion channels) – open an ion pore when ligand binds; subunits have an extracellular binding domain and 4 transmembrane α‑helices. Metabotropic (GPCRs) – 7 transmembrane α‑helices; activate heterotrimeric G proteins (α, β, γ). Kinase‑linked / enzyme‑linked – single‑pass transmembrane receptor with intracellular enzymatic domain. Nuclear receptors – cytoplasmic/nuclear, contain a C‑terminal ligand‑binding region, DNA‑binding zinc fingers, and an N‑terminal activation function. Ligand‑receptor equilibrium $$L + R \rightleftharpoons LR$$ Dissociation constant $Kd = \frac{[L][R]}{[LR]}$; low $Kd$ = high affinity. Efficacy – the ability of a bound ligand to activate the receptor and produce a response (distinct from affinity). Constitutive activity – receptors can have basal signaling in the absence of ligand. 📌 Must Remember Full agonist = 100 % efficacy (maximal response). Partial agonist = sub‑maximal efficacy even at full occupancy (0 % – 100 %). Competitive antagonist = reversible, competes for the same site; can be overcome by high agonist concentration. Irreversible antagonist = forms covalent/very high‑affinity bond; effect reversed only by new receptor synthesis (e.g., omeprazole). Inverse agonist = reduces constitutive activity; negative efficacy. Allosteric modulator = binds a distinct site, altering agonist potency or efficacy (positive or negative). Spare (reserve) receptors – maximal response achievable with <100 % receptor occupancy. Up‑regulation = increase in receptor number → higher sensitivity. Down‑regulation = decrease in receptor number → lower sensitivity. Desensitization – uncoupling from effectors (GPCRs) or internalization (sequestration). 🔄 Key Processes Ligand binding Ligand $L$ encounters receptor $R$ → reversible formation of $LR$ complex. Signal initiation Ionotropic: $LR$ opens channel → rapid ion flux. GPCR: $LR$ promotes GDP→GTP exchange on G‑protein α‑subunit → α‑GTP and βγ activate downstream effectors. Kinase‑linked: $LR$ triggers intrinsic kinase activity → phosphorylation cascade. Nuclear: $LR$ translocates to nucleus → binds DNA → transcriptional regulation. Regulation Prolonged stimulation → desensitization (uncoupling/internalization). Cellular feedback → up‑/down‑regulation of receptor expression. 🔍 Key Comparisons Full agonist vs. Partial agonist – 100 % vs. <100 % maximal response despite full occupancy. Competitive vs. Irreversible antagonist – reversible competition vs. covalent/very high‑affinity binding; only the latter requires new receptor synthesis for recovery. Antagonist vs. Inverse agonist – antagonist blocks agonist but does not affect basal activity; inverse agonist suppresses basal activity. Ionotropic vs. Metabotropic (GPCR) – direct ion flow vs. second‑messenger cascades; speed of response differs (millisecond vs. seconds‑minutes). Allosteric modulator vs. Orthosteric ligand – binds a distinct site and modulates efficacy/potency vs. directly activates/inhibits the primary site. ⚠️ Common Misunderstandings Affinity = efficacy – they are separate; a high‑affinity drug may be a weak agonist. All antagonists are neutral – inverse agonists actively reduce constitutive activity. Full receptor occupancy is required for maximal response – spare receptors allow maximal effect with partial occupancy. Irreversible antagonists are “strong” competitive antagonists – their irreversibility, not potency, defines the effect. GPCR activation always produces the same downstream effect – different G‑protein subtypes (Gs, Gi/o, Gq) lead to distinct pathways. 🧠 Mental Models / Intuition Lock‑and‑key – ligand = key, receptor active site = lock; affinity = how well the key fits. Volume knob – efficacy = how far you turn the knob once the key is in; full agonist = max turn, partial = halfway, inverse = turn the knob down. Empty seats (spare receptors) – a theater can be full even if some seats are empty; the signal is “full” with fewer receptors. Traffic light – agonist = green (go), antagonist = red (stop), inverse agonist = flashing red (slow down baseline). 🚩 Exceptions & Edge Cases Irreversible antagonism – effect persists after washout; recovery depends on receptor synthesis. Constitutive activity – present in many GPCRs; inverse agonists only work when this basal signaling exists. Allosteric modulation – can be positive (enhances agonist effect) or negative (diminishes it); may also alter ligand affinity. Spare receptors – more common in high‑gain systems (e.g., adrenergic heart responses). 📍 When to Use Which Assess affinity → use $Kd$ values (low $Kd$ = high affinity). Predict maximal response → consider spare receptor presence; if dose‑response reaches plateau early, spare receptors likely. Choose antagonist type → if rapid, reversible blockade is needed → competitive; for long‑lasting inhibition → irreversible. Identify inverse agonist → look for drugs that lower basal signaling in a system known to have constitutive activity. Apply allosteric modulators → when you need to fine‑tune agonist potency without competing for the orthosteric site. 👀 Patterns to Recognize Low occupancy + full response → spare receptors. Baseline activity that can be reduced → constitutive activity → inverse agonist possible. Effect not washed out after removal of drug → irreversible antagonist. Drug effect enhanced only in presence of another ligand → positive allosteric modulation. Rapid ion flux after ligand addition → ionotropic receptor; slower, second‑messenger signs → GPCR or enzyme‑linked. 🗂️ Exam Traps “Antagonist” vs. “inverse agonist” – test‑writers may list an antagonist that actually reduces basal activity; choose inverse agonist. Equating high affinity with high efficacy – a high‑affinity partial agonist can produce a modest response; watch for efficacy clues. Assuming all GPCRs desensitize the same way – some undergo phosphorylation, others internalization; answer choices that generalize may be wrong. Misreading “spare receptors” – a question showing maximal response at low agonist concentration is testing spare receptor concept, not high potency. Allosteric site vs. orthosteric site – distractors may label an allosteric modulator as a competitive antagonist; note the distinct binding site.